APA

Pieniaszek H. J., Sy S. K. B., Ebling W., Fossler M. J., Cain V. A., Mondick J. T., Ma S. & Kornhauser D. M. (20030210). Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. : Journal of clinical pharmacology.

Chicago

Pieniaszek Henry J, Sy Sherwin K B, Ebling William, Fossler Michael J, Cain Valerie A, Mondick John T, Ma Su and Kornhauser David M. 20030210. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. : Journal of clinical pharmacology.

Harvard

Pieniaszek H. J., Sy S. K. B., Ebling W., Fossler M. J., Cain V. A., Mondick J. T., Ma S. and Kornhauser D. M. (20030210). Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. : Journal of clinical pharmacology.

MLA

Pieniaszek Henry J, Sy Sherwin K B, Ebling William, Fossler Michael J, Cain Valerie A, Mondick John T, Ma Su and Kornhauser David M. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. : Journal of clinical pharmacology. 20030210.